Shockwave will purchase outstanding Neovasc shares for $27.25 each, valuing the company at around $100 million, according to a Jan. 17 news release from Shockwave. Neovasc specializes in the treatment of refractory angina.
Neovasc’s board approved the transaction, which is expected to close in the first half of 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
